GRI Bio Inc. Market Cap ($3.43 Million)
Market Cap & Net Worth: GRI Bio Inc. (GRI)
GRI Bio Inc. market cap. GRI Bio Inc. (NASDAQ:GRI) has a market capitalization of $3.43 Million ($3.43 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29260 globally and #5996 in its home market, demonstrating a 6.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRI Bio Inc.'s stock price $1.57 by its total outstanding shares 2186115 (2.19 Million).
GRI Bio Inc. Market Cap History (2021–2026)
GRI Bio Inc. market cap history from 2021 to 2026. Data shows change from $35.69 Billion to $3.43 Million (-80.94% CAGR). Check GRI share price today for real-time trading data and today's change.
Index Memberships
GRI Bio Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #843 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2701 of 3165 |
Weight: GRI Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GRI Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRI Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see GRI Bio Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.08x
GRI Bio Inc.'s market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $76.59 Million | $21.77 Million | -$13.04 Million | 3.52x | N/A |
| 2024 | $1.81 Million | $22.54 Million | -$8.21 Million | 0.08x | N/A |
Competitor Companies of GRI by Market Capitalization
Companies near GRI Bio Inc. in the global market cap rankings as of October 31, 2026. See how leveraged is GRI Bio Inc.'s balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to GRI Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of GRI Bio Inc. (2021–2026)
Market capitalization of GRI Bio Inc. from 2021 to today. Between 2021 and today, GRI Bio Inc.'s market cap moved from $35.69 Billion to $ 3.43 Million, with a yearly change of -80.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.43 Million | +536.14% |
| 2025 | $539.53K | -70.21% |
| 2024 | $1.81 Million | -97.64% |
| 2023 | $76.59 Million | -95.57% |
| 2022 | $1.73 Billion | -95.15% |
| 2021 | $35.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of GRI Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.43 Million USD |
| MoneyControl | $3.43 Million USD |
| MarketWatch | $3.43 Million USD |
| marketcap.company | $3.43 Million USD |
| Reuters | $3.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more